Suzhou Fushilai Pharmaceutical Co. Ltd. - Asset Resilience Ratio

Latest as of June 2025: 45.84%

Suzhou Fushilai Pharmaceutical Co. Ltd. (301258) has an Asset Resilience Ratio of 45.84% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Suzhou Fushilai Pharmaceutical Co. Ltd. free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.

Liquid Assets

CN¥977.61 Million
≈ $143.06 Million USD Cash + Short-term Investments

Total Assets

CN¥2.13 Billion
≈ $312.10 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2019–2024)

This chart shows how Suzhou Fushilai Pharmaceutical Co. Ltd.'s Asset Resilience Ratio has changed over time. See Suzhou Fushilai Pharmaceutical Co. Ltd. (301258) balance sheet quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Suzhou Fushilai Pharmaceutical Co. Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Suzhou Fushilai Pharmaceutical Co. Ltd..

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥977.61 Million 45.84%
Total Liquid Assets CN¥977.61 Million 45.84%

Asset Resilience Insights

  • Very High Liquidity: Suzhou Fushilai Pharmaceutical Co. Ltd. maintains exceptional liquid asset reserves at 45.84% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Suzhou Fushilai Pharmaceutical Co. Ltd. Industry Peers by Asset Resilience Ratio

Compare Suzhou Fushilai Pharmaceutical Co. Ltd.'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Ascendis Pharma AS
NASDAQ:ASND
Biotechnology 0.00%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Spyre Therapeutics Inc.
NASDAQ:SYRE
Biotechnology 84.34%
3SBio Inc
F:83B
Biotechnology 10.64%
Soleno Therapeutics Inc
NASDAQ:SLNO
Biotechnology 20.15%
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
Biotechnology 0.02%
Novavax Inc
NASDAQ:NVAX
Biotechnology 53.87%
BB Biotech AG
SW:BION
Biotechnology 0.05%

Annual Asset Resilience Ratio for Suzhou Fushilai Pharmaceutical Co. Ltd. (2019–2024)

The table below shows the annual Asset Resilience Ratio data for Suzhou Fushilai Pharmaceutical Co. Ltd..

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 53.80% CN¥1.12 Billion
≈ $164.35 Million
CN¥2.09 Billion
≈ $305.50 Million
+3.25pp
2023-12-31 50.54% CN¥1.07 Billion
≈ $156.51 Million
CN¥2.12 Billion
≈ $309.65 Million
-4.78pp
2022-12-31 55.33% CN¥1.16 Billion
≈ $169.89 Million
CN¥2.10 Billion
≈ $307.06 Million
+53.10pp
2021-12-31 2.23% CN¥21.61 Million
≈ $3.16 Million
CN¥970.31 Million
≈ $141.99 Million
-13.00pp
2020-12-31 15.22% CN¥120.00 Million
≈ $17.56 Million
CN¥788.25 Million
≈ $115.35 Million
+12.42pp
2019-12-31 2.81% CN¥21.10 Million
≈ $3.09 Million
CN¥751.44 Million
≈ $109.96 Million
--
pp = percentage points

About Suzhou Fushilai Pharmaceutical Co. Ltd.

SHE:301258 China Biotechnology
Market Cap
$322.75 Million
CN¥2.21 Billion CNY
Market Cap Rank
#14562 Global
#4347 in China
Share Price
CN¥24.06
Change (1 day)
-0.17%
52-Week Range
CN¥24.06 - CN¥39.02
All Time High
CN¥63.49
About

Suzhou Fushilai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and health care raw materials in China and internationally. The company offers lipoic acid products comprising granular alpha lipoic acid, R-lipoic acid, r-lipoic acid tromethamine salt, and … Read more